GlaxoSmithKline Withdraws Patent Applications for Antiretrovirals Abacavir, Trizivir in India
December 10, 2007
GlaxoSmithKline recently withdrew the patent applications for its antiretroviral drugs Abacavir and Trizivir in India, the Economic Times reports. According to the Times, GSK formally withdrew its application for Abacavir, and its application for Trizivir was deemed withdrawn after the company requested that India's Patent Office not examine the case.
India's patent law, which went into effect in January 2005, allows patents for products that are new inventions developed after 1995, when India joined the World Trade Organization, or for an updated drug that exhibits improved efficacy (Kaiser Daily HIV/AIDS Report, 8/6). According to the Times, the company thought it necessary to withdraw the applications rather than be rejected because a rejection could weaken the company's chances of securing patents in other developing countries. Medecins Sans Frontieres and I-MAK had challenged the patent applications on behalf of the Indian Network of Positive People (Economic Times, 12/7).
First-Line Triple-Combination Antiretroviral Therapy Provides Long-Term Protection Against AIDS-Related Illnesses, Study Says
Millennium Challenge Corporation Could Receive Budget Cuts Because of "Slow Pace" in Launching Development Projects, New York Times Reports
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.